Serum levels of reactive oxygen metabolites at 12 weeks during tocilizumab therapy are predictive of 52 weeks-disease activity score-remission in patients with rheumatoid arthritis

BACKGROUND: To verify whether serum levels of reactive oxygen metabolites (ROM) are predictive of future clinical remission in patients with rheumatoid arthritis (RA) receiving tocilizumab (TCZ) therapy. METHODS: A total of 46 patients with RA receiving TCZ therapy were enrolled in this study. Patie...

Cijeli opis

Spremljeno u:
Bibliografski detalji
Izdano u:BMC Rheumatol
Glavni autori: Nakajima, Arata, Terayama, Keiichiro, Sonobe, Masato, Aoki, Yasuchika, Takahashi, Hiroshi, Akatsu, Yorikazu, Saito, Junya, Taniguchi, Shinji, Yamada, Manabu, Kubota, Ayako, Nakagawa, Koichi
Format: Artigo
Jezik:Inglês
Izdano: BioMed Central 2019
Teme:
Research Article
Online pristup:https://ncbi.nlm.nih.gov/pmc/articles/PMC6912997/
https://ncbi.nlm.nih.gov/pubmed/31891116
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1186/s41927-019-0096-1
Oznake: Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!

Similar Items